Blood is made up of four main components: plasma, red blood cells, white blood cells, and platelets. Plasma is the liquid portion that carries everything else, while the three cellular (or cell-like) elements are suspended within it. Together, these four parts handle an enormous range of jobs, from delivering oxygen and fighting infections to sealing wounds and ferrying hormones. The proportions and properties of each component reveal a lot about how the body works and, when something goes wrong, what a doctor looks for first.
Plasma
Plasma is the straw-colored liquid that makes up roughly 55 percent of your blood’s total volume. It is mostly water, about 90 percent by weight, but that remaining 10 percent is packed with dissolved substances the body depends on: proteins, electrolytes, glucose, hormones, dissolved gases, and waste products heading to the kidneys for disposal.
The electrolytes in plasma, especially sodium, chloride, and bicarbonate, are responsible for about 85 percent of the total osmotic pressure that keeps water distributed correctly between your blood vessels and the surrounding tissues.1Bulletin of Science and Practice. Water-Salt Homeostasis of the Human Body and Electrolytic Composition of the Internal Liquid Environment When that balance shifts even slightly, water moves across cell membranes by osmosis, which is why dehydration or an electrolyte imbalance can affect blood pressure and organ function so quickly.
Plasma proteins fall into three broad families: albumin, globulins, and fibrinogen. Albumin is the most abundant and acts as a molecular taxi, binding to fatty acids, drugs, and hormones to shuttle them through the bloodstream. It also helps maintain the osmotic pull that keeps fluid from leaking out of capillaries. Globulins include antibodies produced by the immune system as well as transport proteins for metals and fats. Fibrinogen is the precursor to fibrin, the mesh-like protein that forms the structural backbone of a blood clot. Research dating back decades identified the liver as the almost exclusive site of fibrinogen production, and likely a major source of other serum proteins as well.2JAMA Network. PLASMA PROTEINS
Red Blood Cells
Red blood cells, also called erythrocytes, are the most numerous cells in your blood by a wide margin. A single drop contains millions of them, and their sole purpose is gas exchange: picking up oxygen in the lungs and dropping it off in tissues, then carrying carbon dioxide back for exhalation. They accomplish this with hemoglobin, an iron-containing protein that binds oxygen reversibly. Hemoglobin is also what gives blood its red color, bright scarlet when oxygenated, darker when not.
What makes red blood cells unusual is their shape. They are biconcave discs, thinner in the middle and thicker at the edges, a bit like a donut that never fully punched through. This shape is not decorative. It maximizes surface area for gas exchange and gives the cell the flexibility to squeeze through capillaries narrower than the cell itself.3PubMed Central. Shape and Biomechanical Characteristics of Human Red Blood Cells in Health and Disease Mature human red blood cells also lack a nucleus, which frees up interior space for more hemoglobin. That trade-off means the cell cannot repair itself or divide, so it has a finite lifespan.
On average, a red blood cell circulates for about 120 days. After that, it is recognized as aged and swallowed by immune cells called macrophages, mostly in the spleen and liver. This cleanup is remarkably efficient: macrophages consume roughly five million worn-out red blood cells every second without spilling significant hemoglobin into the plasma.4PubMed Central. How Do Red Blood Cells Die? The iron from recycled hemoglobin gets sent back to the bone marrow to be built into new cells.
The Spleen’s Role in Shaping Red Blood Cells
The spleen does more than recycle old red blood cells. It also shapes new ones. When freshly made red blood cells, called reticulocytes, leave the bone marrow, they still contain leftover internal particles from their development. As these young cells pass through narrow slits in the spleen, non-deformable particles inside them get physically squeezed out, a process sometimes called “pitting.” Computational modeling has shown that the spleen’s filtering architecture is what drives this mechanical editing.5PubMed Central. How the spleen reshapes and retains young and old red blood cells: A computational investigation
Those same simulations found that immature red blood cells shed bits of their outer membrane as they pass through the spleen’s slits, gradually shrinking and acquiring the classic biconcave disc shape. This helps explain a clinical observation: people who have had their spleen removed tend to have larger-than-normal red blood cells, because the cells never go through that trimming process. At the end of a red blood cell’s life, the spleen is also where the cell tends to get trapped, since aging makes it stiffer and less able to squeeze through those narrow passages.
White Blood Cells
White blood cells, or leukocytes, are the immune system’s mobile workforce. They are far less numerous than red blood cells, typically making up less than one percent of your blood’s volume, but their impact is outsized. White blood cells patrol the bloodstream, detect threats, coordinate immune responses, and directly destroy pathogens or infected cells.
They fall into three main groups: granulocytes, monocytes, and lymphocytes.6Langenbeck’s Archives of Surgery. Leukocytes, the Janus cells in inflammatory disease Granulocytes include neutrophils (the most common white blood cell, specialized in eating bacteria), eosinophils (involved in allergic reactions and parasitic infections), and basophils (which release histamine during inflammation). Monocytes circulate in the blood and then migrate into tissues where they mature into macrophages, the heavy-duty cleanup crew that engulfs pathogens and dead cells. Lymphocytes include T cells, B cells, and natural killer cells, and they handle the more targeted side of immunity, producing antibodies, killing virus-infected cells, and building immunological memory.
One of the more fascinating things about white blood cells is how they leave the bloodstream to reach an infection or injury site. In a process called extravasation, a white blood cell first rolls along the inner wall of a blood vessel, then sticks to it, and finally squeezes through the gaps between the cells that line the vessel wall.7PubMed Central. Extravasation of leukocytes in comparison to tumor cells This squeezing, called diapedesis, can happen between endothelial cells or, in some cases, directly through a single endothelial cell.8PubMed Central. Getting leukocytes to the site of inflammation The cell essentially shape-shifts its way out of the blood vessel and into the surrounding tissue, guided by chemical signals released at the site of damage.
Platelets
Platelets, or thrombocytes, are the smallest of the cellular elements in blood and are technically not cells at all. They are tiny, disc-shaped fragments of cytoplasm that have no nucleus.9PubMed Central. Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets They originate from enormous precursor cells called megakaryocytes, which live in the bone marrow. A single megakaryocyte can release thousands of platelets through an elaborate process of internal remodeling and fragmentation.10PubMed Central. The biogenesis of platelets from megakaryocyte proplatelets
The primary job of platelets is stopping bleeding. When a blood vessel is injured, proteins in the exposed vessel wall, particularly collagen and von Willebrand factor, act as signals that platelets latch onto.11PubMed. Platelet physiology and thrombosis This initial adhesion triggers the platelet to change shape, extend sticky projections, and release chemical signals that recruit more platelets to the site. The platelets aggregate into a plug, and simultaneously activate clotting factors in the plasma that build a reinforcing fibrin mesh over the plug. This whole sequence, from adhesion to activation to aggregation, is often described as hemostasis.12PubMed Central. Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis
Despite being small and lacking a nucleus, platelets are biochemically active. They carry a surprising array of signaling molecules, growth factors, and inflammatory mediators inside granules that get released upon activation. This means platelets are not just passive plug-builders; they actively influence wound healing, inflammation, and even interactions with immune cells. A normal platelet count ranges roughly from 150,000 to 400,000 per microliter of blood, and they circulate for about 8 to 10 days before being cleared.
Where Blood Cells Come From
All blood cells, red and white, along with platelets, trace their origin to a single type of precursor in the bone marrow: the hematopoietic stem cell. These stem cells are self-renewing, meaning they can copy themselves, but they can also commit to becoming a specialized cell type. The process unfolds as a branching tree. A stem cell first differentiates into a progenitor that is committed to either the myeloid or the lymphoid lineage, two broad arms of blood cell development.13PubMed Central. Myeloid Cell Origins, Differentiation, and Clinical Implications
The myeloid branch gives rise to red blood cells, platelets, and most of the granulocytes and monocytes. The lymphoid branch produces the lymphocytes: T cells, B cells, and natural killer cells. Each step along the way involves the progressive loss of the ability to become other cell types, so by the time a progenitor is destined to become, say, a red blood cell, it can no longer become a neutrophil.14PubMed Central. Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors The bone marrow produces hundreds of billions of new blood cells every day, a constant and precisely regulated output that adjusts in response to the body’s needs, ramping up during infection or after blood loss.
Blood Types and Surface Antigens
The surface of a red blood cell is studded with molecules that vary from person to person, and these surface markers are the basis of blood typing. Most people are familiar with the ABO system and the Rh factor (“positive” or “negative”), but those are just two of many classification systems. The International Society of Blood Transfusion recognizes 33 distinct blood group systems, each defined by different antigens on the red cell membrane.15PubMed Central. Blood groups systems
In everyday medicine, ABO and Rh are the ones that matter most for transfusion safety. If you receive blood with antigens your immune system does not recognize, your body can mount an aggressive response that destroys the donated red blood cells, a potentially life-threatening reaction. The less well-known blood group systems, like Kell, Duffy, and Kidd, usually only become clinically relevant in patients who receive many transfusions over time and develop antibodies against these rarer antigens. This is a particular concern for people with sickle cell disease or other conditions requiring chronic transfusion therapy.
What a Complete Blood Count Tells You
The single most commonly ordered blood test is the complete blood count, or CBC. It measures the numbers and characteristics of each cellular component: red blood cell count, hemoglobin concentration, white blood cell count and its breakdown by subtype, and platelet count. Changes in any of these values can point toward a wide range of conditions, from infection and anemia to leukemia and clotting disorders.
More recently, researchers have found that several CBC-derived measurements can serve as surprisingly useful markers for diseases you might not initially associate with blood counts. Ratios like the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio, as well as measures like red cell distribution width (a measure of how variable your red blood cells are in size) and mean platelet volume, have been linked to the risk of cardiovascular disease, type 2 diabetes, and metabolic syndrome.16PubMed Central. Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review These are not standalone diagnostic tools, but they add useful information on top of a cheap and widely available test.
Why Human Red Blood Cells Have No Nucleus
Almost all other vertebrates, from birds to fish to reptiles, have red blood cells that retain their nucleus. Mammals are the major exception. Losing the nucleus appears to have been an evolutionary strategy to pack more hemoglobin into each cell and to make the cell more deformable, allowing it to pass through the tiniest capillaries more easily. Research comparing red blood cell properties across hundreds of species found that birds and mammals end up with similar hemoglobin concentrations per cell despite very different cell designs, suggesting that ejecting the nucleus was one way to solve the problem of efficient oxygen delivery rather than the only way.17PubMed. Revisiting the question of nucleated versus enucleated erythrocytes in birds and mammals
The practical consequence is a difference in how blood flows. Nucleated red blood cells are stiffer and bulkier, which makes them harder to push through narrow vessels. Studies measuring blood viscosity in small tubes found that suspensions of nucleated red blood cells (from birds, in this case) had significantly higher viscosity than human blood at the same vessel diameter and cell concentration.18PubMed. Comparative rheology of nucleated and non-nucleated red blood cells. II. Rheological properties of avian red cells suspensions in narrow capillaries The mammalian solution of ditching the nucleus likely allows for more efficient delivery of oxygen through the body’s smallest blood vessels, which matters a great deal for large, metabolically active animals.
Red Blood Cell Vesicles and Cell-to-Cell Communication
Until fairly recently, red blood cells were thought of as passive cargo trucks: load up with oxygen, drop it off, repeat. But research over the past couple of decades has revealed that red blood cells release tiny membrane-bound packages called extracellular vesicles into the surrounding plasma. These vesicles carry bioactive molecules and can act as signals to other cells, functioning as a form of cell-to-cell communication.19PubMed Central. Extracellular Vesicles from Red Blood Cells and Their Evolving Roles in Health, Coagulopathy and Therapy
The implications are still being worked out, but some findings are already striking. One study found that microvesicles shed by red blood cells interact with neutrophils, a key type of white blood cell, via two separate pathways: direct fusion with the neutrophil’s outer membrane and internalization into the neutrophil. Functionally, these vesicles reduced the neutrophil’s ability to engulf bacteria, suggesting that red blood cells can actively modulate immune responses.20PubMed Central. Human red blood cells release microvesicles with distinct sizes and protein composition that alter neutrophil phagocytosis The amounts and types of vesicles released can also change in disease states, making them a potential marker for conditions ranging from clotting disorders to malaria.
The Search for Artificial Blood
Given how critical each blood component is, scientists have spent decades trying to create a synthetic substitute, something that could be manufactured at scale, stored without refrigeration, and transfused into anyone regardless of blood type. Despite many attempts, no blood substitute has been approved by the U.S. Food and Drug Administration. The challenges are steep: replicating even the oxygen-carrying function of red blood cells, let alone the clotting, immune, and signaling roles of the other components, has proven extraordinarily difficult.21PubMed Central. Artificial Blood: The History and Current Perspectives of Blood Substitutes
Most research has focused on hemoglobin-based oxygen carriers, which use purified or chemically modified hemoglobin to transport oxygen. Early versions ran into problems with toxicity and short circulation times. A more recently developed hemoglobin-based carrier has shown enough promise in early clinical trials to receive “Orphan Drug” status from the FDA, a designation that provides incentives for developing treatments for rare conditions, but approval for general use remains elusive. Part of the difficulty is that real blood does so many things at once. Even a product that carries oxygen well does nothing for clotting, immune defense, or the subtle regulatory signaling that plasma proteins and extracellular vesicles handle. For now, donated human blood remains irreplaceable, which is why blood banks around the world emphasize the ongoing need for donors.